Skip to main content
NewslettersWatchlist

Microbix J(MBX-T)
TSX

Today's Change
Real-Time Last Update
Day Low0.3550
Day High0.3550
Open:0.3550
Price movement based on the high, low and last over the given period.
Previous Close
52-Week High/Low
Volume
Average Volume
Price/Earnings (TTM)
Forward Annual Dividend & Yield
Market Capitalization, $M
5-Day Change
Select a category then submit the form to load news
Automated Summaries - The Globe and Mail
Closing Bell: Microbix J up on Thursday (MBX)
Baystreet
Stocks in play: Microbix Biosystems Inc.
GlobeNewswire
Microbix Presenting at the 2024 Bloom Burton Conference
GlobeNewswire
Microbix Announces Annual and Special Meeting Voting Results
GlobeNewswire
Microbix’s Clot-Buster Drug Project Advances
Baystreet
Stocks in play: Microbix Biosystems Inc.
GlobeNewswire
Microbix Unveils Test Controls for Head and Neck Cancer
GlobeNewswire
Microbix Announces Issuance of Stock Options
GlobeNewswire
Microbix Reports Record Results for Q1 Fiscal 2024
GlobeNewswire
Microbix Schedules Release of Results for Q1 Fiscal 2024 
GlobeNewswire
Microbix Unveils Test Control for Gastric Ulcer Disease Pathogen
Baystreet
Stocks in play: Microbix Biosystems Inc.
GlobeNewswire
Microbix Achieves Further QAPs Sales Record
GlobeNewswire
Microbix Reports Results for Q4 & Full-Year Fiscal 2023
Baystreet
Stocks in play: Microbix Biosystems Inc.
GlobeNewswire
Microbix & Seegene USA Jointly Enhancing Lab Test Accuracy
GlobeNewswire
Microbix & BioGX Collaborate on real-time PCR Assays & Controls
Baystreet
Stocks in play: Microbix Biosystems Inc.
GlobeNewswire
Microbix Announces Initiation of Normal Course Issuer Bid
Baystreet
Stocks in play: Microbix Biosystems Inc.
GlobeNewswire
Microbix Presenting at Florida Capital Event Conference
GlobeNewswire
Microbix Clot-Buster Drug Fully-Funded For Return to U.S. Market
Baystreet
Stocks in play: Microbix Biosystems Inc.
GlobeNewswire
Microbix & Ulisse Biomed Collaborate on HPV Controls & Assays
Baystreet
Stocks in play: Microbix Biosystems Inc.
GlobeNewswire
Microbix QAPs Supporting HPV Testing in Ireland
Baystreet
Stocks in play: Microbix Biosystems Inc.
GlobeNewswire
Microbix Presenting at Muskoka Capital Conference
Baystreet
Stocks in play: Microbix Biosystems Inc.
GlobeNewswire
Microbix Achieves New QAPs Sales Record
GlobeNewswire
Microbix Honours the Passing of its Founder
ACCESSWIRE
Keynote Speakers and 34 Companies to Present at the Planet MicroCap Showcase: VANCOUVER on September 6-7, 2023 at the Fairmont Waterfront Vancouver

Profile

Microbix Biosystems Inc develops biological products and technologies. The company manufactures and develops cell culture-based biological products and technologies. It has developed and acquired two technologies; Kinlytic and LumiSort. The company's operating segment includes Antigen, QAPs DxTM and Other Includes Kinlytic. It generates maximum revenue from the Antigen QAPs segment. Geographically, it derives a majority of revenue from North America.

All market data (will open in new tab) is provided by Barchart Solutions. Copyright © 2024.

Information is provided 'as is' and solely for informational purposes, not for trading purposes or advice. For exchange delays and terms of use, please read disclaimer (will open in new tab).

Copyright © 2024 Morningstar. All Rights Reserved. The information contained herein: (1) is proprietary to Morningstar and/or its content providers; (2) may not be copied or distributed; and (3) is not warranted to be accurate, complete or timely. Neither Morningstar nor its content providers are responsible for any damages or losses arising from any use of this information. Past performance is no guarantee of future results.